Skip to main content

Fetzima FDA Approval History

FDA Approved: Yes (First approved July 25, 2013)
Brand name: Fetzima
Generic name: levomilnacipran
Dosage form: Extended-Release Capsules
Company: Allergan plc
Treatment for: Depression

Fetzima (levomilnacipran) is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder.

Development timeline for Fetzima

Jul 26, 2013Approval Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of Fetzima for the Treatment of Major Depressive Disorder in Adults
Sep 27, 2012Forest Laboratories Submits New Drug Application for Levomilnacipran for the Treatment of Major Depressive Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.